ORCA Therapeutics BV

ORCA Therapeutics BV is a biopharmaceutical company founded in 2005 and is focused on the development of novel drug candidates for treatment of cancer using Oncolytic Replication Competent Agents (ORCA). ORCA Therapeutics’ technology and IP portfolio originates from the research performed at the Department of Medical Oncology at the VU University Medical Center (VUmc) in Amsterdam, the Netherlands.

The company has a platform of technologies that are predominantly based on highly engineered oncolytic adenoviruses. ORCA Therapeutics is currently preparing its lead product ORCA-010 for testing in clinical trials.